Newly developed apolipoprotein A-I mimetic peptide promotes macrophage reverse cholesterol transport in vivo》.pdfVIP

International Journal of Cardiology 192 (2015) 82–88 Contents lists available at ScienceDirect International Journal of Cardiology journal homepage: www. else vi er. com/ locate/ijcard Newly developed apolipoprotein A-I mimetic peptide promotes macrophage reverse cholesterol transport in vivo Tomohiko Shimizu a,1, Hiroyuki Tanigawa a,1, Shin-ichiro Miura a,b,⁎, Takashi Kuwano a, Kohei Takata a, Yasunori Suematsu a, Satoshi Imaizumi a, Eiji Yahiro a, Bo Zhang c, Yoshinari Uehara a,b, Keijiro Saku a,b,d,⁎ a Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan b Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan c Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan d Department of Advanced Therapeutics for Cardiovascular Disease, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan a r t i c l e i n f o a b s t r a c t Article history: Background: We elucidated the effect of newly developed Fukuoka Apolipoprotein A-I Mimetic Peptide (FAMP) Received 6 December 2014 on in vivo macrophage reverse cholesterol transport (RCT) and the underlying mechanisms. Received in revised form 26 March 2015 Methods and results: Cholesteryl ester transfer protein transgenic mice were divided into FAMP, and placebo Accepted 6 May 2015 control groups, and injected with FAMP or phosphate buffer saline intraperitoneally for 5 days. The FAMP Available online 7 May 2015